Lilly’s Eczema Drug Gets Canadian Reimbursement Nod, But Stock Slips 2.33%

Eli Lilly’s (LLY) Canadian subsidiary announced on July 8 that its drug for moderate-to-severe atopic dermatitis (eczema), Ebglyss® (lebrikizumab), has received a positive reimbursement recommendation from the Canadian Drug Agency (CDA-AMC) and a letter of intent from the pan-Canadian Pharmaceutical Alliance (pCPA). The milestone marks a critical step toward national public drug coverage for the drug. However, as of the close on July 10, Lilly shares were at $1,188.58, down 2.33% from the prior close of $1,216.95, with an intraday low of $1,178.32.

Canadian Market Access Breakthrough

According to a press release from Lilly Canada, CDA-AMC issued a conditional positive recommendation for Ebglyss® for patients with moderate-to-severe atopic dermatitis.^[BioSpace] Prior to this, the drug had already received a positive recommendation from Quebec’s health technology assessment body, INESSS, on August 1, 2024, and was subsequently listed on the province’s public drug insurance plan (RAMQ) reimbursement list.^[BioSpace]

The pCPA’s letter of intent with Lilly Canada means Ebglyss® is now on track for reimbursement under public drug plans across all provinces. Mathilde Merlet, general manager of Lilly Canada, said in a statement: “We are encouraged by CDA-AMC’s positive recommendation for Ebglyss®. The pCPA’s decision to sign a letter of intent will give patients across Canada access to an advanced biologic that is administered every four weeks, offering durable long-term efficacy and a proven safety profile, providing physicians and patients with another option in a treatment area with significant unmet need.”^[BioSpace]

Unmet Need in Eczema Treatment

Atopic dermatitis is a common chronic inflammatory skin condition marked by intense itching and recurrent lesions. Patients with moderate-to-severe disease often respond poorly to existing therapies, severely impacting quality of life. Merlet noted in the statement: “In clinical practice, moderate-to-severe atopic dermatitis remains a difficult condition to manage, with many patients continuing to experience persistent symptoms, including itch.”^[BioSpace]

Ebglyss® (lebrikizumab) is a monoclonal antibody targeting IL-13, a key cytokine in the inflammatory process of atopic dermatitis. The drug is administered via subcutaneous injection every four weeks, designed to offer a convenient treatment option. The CDA-AMC recommendation aligns Ebglyss®’s Canadian reimbursement scope with Quebec and other global markets where patients are already benefiting from its therapeutic value.

Lilly Stock Recent Performance and Market Backdrop

Despite the positive Canadian progress for Ebglyss®, Lilly shares fell in trading on July 10. The stock closed at $1,188.58, down 2.33% from the prior close of $1,216.95, after opening at $1,210.31 and hitting an intraday high of $1,212.96 and a low of $1,178.32. The decline came against a broader pharma news backdrop, including the unexpected failure of AstraZeneca and Ionis’s Wainua in an ATTR cardiomyopathy trial, and market volatility from Kailera Therapeutics’ oral obesity drug data.^{[pharmaphorum][pharmaphorum]}

Separately, on the patent litigation front, Pfizer’s Wyeth LLC failed to persuade the Federal Circuit to overturn a ruling that invalidated two patents for its cancer drug Vizimpro, after Wyeth had previously won a $107.5 million patent infringement verdict against AstraZeneca’s Tagrisso.^{[Bloomberg Law]}

Analyst and Industry Observations

For Lilly, the Canadian market access progress for Ebglyss® is a meaningful step for its dermatology pipeline. The drug faces competition from established products like Sanofi/Regeneron’s Dupixent (dupilumab), another biologic for moderate-to-severe atopic dermatitis. Ebglyss®’s differentiating advantage is its every-four-week dosing schedule, which may offer patients a more convenient treatment option.

In the broader pharma landscape, the failure of AstraZeneca and Ionis’s Wainua in an ATTR cardiomyopathy trial has sparked discussion about the outlook for TTR silencers. According to BioSpace, Stifel analysts noted in a July 10 report: “This study should have worked because we know TTR silencers are effective.”^[BioSpace] The event has put the spotlight on companies like Alnylam, with Truist Securities analysts saying Wainua’s failure “is a near-term ‘win’ for ALNY, as it leaves Amvuttra as the only approved TTR silencer for ATTR-CM.”^[BioSpace]

This content is for informational purposes only and does not constitute investment advice, trading advice, or any guarantee of returns.